Shuichi Kitada

Shuichi Kitada

Auto-generated profile, based on publicly available information

Shuichi Kitada

Department of Cardiology, Nagoya City University Graduate School of Medical Sciences

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2020 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
MKMarina Kato
Marina Kato
SKShuichi Kitada
Shuichi Kitada
YKYu Kawada
Yu Kawada
KNKosuke Nakasuka
Kosuke Nakasuka
SKShohei Kikuchi
Shohei Kikuchi
NONobuyuki Ohte
Nobuyuki Ohte
Background. Left ventricular (LV) ejection fraction (EF) and LV volumes were reported to have prognostic efficacy in cardiac diseases. In particular, the end-systolic volume index (LVESVI) has been featured as the most reliable prognostic indicator. However, such efficacy in patients with LVEF ≥ 50% has not been elucidated. Methods. We screened the patients who received cardiac catheterization to evaluate coronary artery disease concomitantly with both left ventriculography and LV pressure recording using a catheter-tipped micromanometer and finally enrolled 355 patients with LVEF ≥ 50% and no history of heart failure (HF) after exclusion of the patients with severe coronary artery stenosis requiring early revascularization. Cardiovascular death or hospitalization for HF was defined as adverse events. The prognostic value of LVESVI was investigated using a Cox proportional hazards model. Results. A univariable analysis demonstrated that age, log BNP level, tau, peak − dP/dt, LVEF, LV end-diastolic volume index (LVEDVI), and LVESVI were associated with adverse events. A correlation analysis revealed that LVESVI was significantly associated with log BNP level (r = 0.356, p<0.001), +dP/dt (r = −0.324, p<0.001), −dP/dt (r = 0.391, p<0.001), and tau (r = 0.337, p<0.001). Multivariable analysis with a stepwise procedure using the variables with statistical significance in the univariable analysis revealed that aging, an increase in BNP level, and enlargement of LVESVI were significant prognostic indicators (age: HR: 1.071, 95% CI: 1.009–1.137, p=0.024; log BNP : HR : 1.533, 95% CI: 1.090–2.156, p=0.014; LVESVI : HR : 1.051, 95% CI: 1.011–1.093, p=0.013, respectively). According to the receiver-operating characteristic curve analysis for adverse events, log BNP level of 3.23 pg/ml (BNP level: 25.3 pg/ml) and an LVESVI of 24.1 ml/m2 were optimal cutoff values (BNP : AUC : 0.753, p<0.001, LVESVI : AUC : 0.729, p<0.001, respectively). Conclusion. In patients with LVEF ≥ 50%, an increased LVESVI is related to the adverse events. LV contractile performance even in the range of preserved LVEF should be considered as a role of a prognostic indicator.

24 September 2013 in Echocardiography
Verified
Journal Article
Open access
PDF file
TKTomoko S. Kato
Tomoko S. Kato
PCPaolo C. Colombo
Paolo C. Colombo
NNNadav Nahumi
Nadav Nahumi
SKShuichi Kitada
Shuichi Kitada
HTHiroo Takayama
Hiroo Takayama
NUNir Uriel
Nir Uriel
Thrombus formation inside of the pump is a major cause for device malfunction following the left ventricular assist device (LVAD) implantation. We recently established a novel ramp test protocol facilitating continuous bedside echo monitoring to optimize LVAD function and diagnosing device malfunctions. We describe a case of 29‐year‐old woman undergoing HeartMate II LVAD implantation, in whom serial ramp studies were used to diagnose intra‐device thrombus after device implantation. The 1st ramp study at postoperative day (POD) 26 revealed adequate reduction in ventricular size according to the increase in LVAD speed (left ventricular end‐diastolic diameter [LVEDD] at minimum and maximum speeds, 68 and 37 mm, respectively). The patient was discharged home and received routine anticoagulation maintenance therapy. However, a 2nd ramp test was performed on POD 56 due to increased lactase dehydrogenase and brain natriuretic peptide levels and showed marked increase in left ventricle (LV) chamber size without adequate response to the LVAD speed changes (LVEDD at minimum and maximum speeds, 88 and 76 mm, respectively). Given the suspicion for partial pump thrombosis, the patient was immediately hospitalized and received intravenous heparin infusion. After the optimization of the intensive anticoagulation therapy, the patient underwent a 3rd ramp study, which showed a remarkable improvement of the adequate response to LVAD speed changes. The patients eventually underwent cardiac transplant successfully, and the partial clot was found inside of the pump. This case demonstrates the usefulness of serial ramp studies in patients who are suspected to have device thrombosis.

21 September 2017 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
SKShuichi Kitada
Shuichi Kitada
SKShohei Kikuchi
Shohei Kikuchi
TTTakeshi Tsujino
Takeshi Tsujino
TMTohru Masuyama
Tohru Masuyama
NONobuyuki Ohte
Nobuyuki Ohte
Cardiac function varies in the population of patients with heart failure (HF) with preserved left ventricular ejection fraction (LVEF; HFpEF). This study investigated the heterogeneity of clinical features associated with HF and the prognostic value of BNP levels in patients with HFpEF. The study enrolled 288 patients with stable HF and serum creatinine 40%, n = 205). Patients with HFpEF were further categorized as having relatively low LVEF (HFrlEF; EF 40–60%, n = 107) or as having relatively high LVEF (HFrhEF; EF ≥ 60%, n = 98). We defined cardiovascular death and hospitalization for HF as adverse events and evaluated the prognostic value of the BNP levels in each group. There was no significant difference in event-free survival between HFpEF and HFrEF patients or between HFrhEF and HFrlEF patients. A multivariate Cox proportional hazards model revealed that the BNP level was an independent predictor of adverse events in HFrEF patients (hazard ratio: 4.088, 95% confidence interval: 1.178–14.179, P = 0.027) and in HFrlEF patients (hazard ratio: 14.888, 95% confidence interval: 4.969–44.608, P < 0.001) but not in HFrhEF patients (P = 0.767). The BNP level has prognostic value in HFrlEF but not in HFrhEF. This indicates that HFrhEF and HFrlEF are distinct entities that may require different approaches for the management of HF.

27 October 2016 in Journal of International Medical Research
Verified
Journal Article
Open access
SKShuichi Kitada
Shuichi Kitada
SKShohei Kikuchi
Shohei Kikuchi
HSHiroo Sonoda
Hiroo Sonoda
AYAtsuhiro Yoshida
Atsuhiro Yoshida
NONobuyuki Ohte
Nobuyuki Ohte
Objective: To investigate the association between arginine vasopressin (AVP) levels and loop diuretic (LD) therapy in patients with heart failure and to determine if AVP levels are a prognostic indicator of treatment failure. Methods: Patients with stable heart failure and reduced (< 40%) left ventricular ejection fraction (LVEF) were divided into those treated with (LD) or without LD (NLD). The LD group was separated into subgroups of high (> 6.5 pg/dl) and low (≤ 6.5 pg/dl) AVP levels. The clinical and biochemical characteristics of the two groups were compared and the prognostic value of AVP levels in heart failure evaluated. Results: Of the 63 patients enrolled into the study, 41 (65.1%) were in the LD group and 22 (34.9%) were in the NLD group. Despite no differences between groups in LVEF, creatinine clearance, or brain natriuretic peptide, the LD group had significantly higher AVP levels compared with the NLD group. A Cox proportional-hazards model showed that AVP was an independent predictor of adverse events. In addition, the elevation in AVP in the LD group was inversely correlated with an increase in free water clearance but not serum osmolality and was related to poor outcome. Conclusions: Elevated AVP levels in patients with heart failure who received LD therapy were associated with a poor prognosis. Loop diuretics may induce non-osmolar AVP release, which can worsen heart failure.

1 April 2025 in JACC: Asia
Verified
Journal Article
Open access
SKShuichi Kitada
Shuichi Kitada
YKYu Kawada
Yu Kawada
YSYasuhiro Shintani
Yasuhiro Shintani
JYJunki Yamamoto
Junki Yamamoto
SKShohei Kikuchi
Shohei Kikuchi
YSYoshihiro Seo
Yoshihiro Seo
Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) occurs at a high prevalence in older patients with left ventricular (LV) hypertrophy. However, detecting ATTRwt-CA using echocardiography is challenging. This study identified echocardiographic findings characterizing ATTRwt-CA compared with monoclonal immunoglobulin light chain cardiac amyloidosis (CA) and hereditary transthyretin CA. We conducted a multicenter, retrospective study on the echocardiographic findings characterizing ATTRwt-CA. J-CASE (Japan Cardiac Amyloidosis Survey of typical Echocardiographic findings) analyzed echocardiographic data in 311 patients with histologically proven amyloid deposition in the myocardium and diagnosis of transthyretin CA or monoclonal immunoglobulin light chain CA. Among the cohort, 172 patients (55.3%) were diagnosed with ATTRwt-CA. A multiple discriminant analysis revealed that LV hypertrophy with a more extensive LV mass index but relatively modest interventricular septum thickening and enlargement of maximal papillary muscle diameter were significant echocardiographic findings characterizing ATTRwt-CA. In addition to the patient backgrounds such as advanced age, male sex, concomitant diabetes mellitus, hyperlipidemia, carpal tunnel syndrome, and paroxysmal atrial fibrillation, the discriminant model, including these echocardiographic findings showed significant discriminant power of ATTRwt-CA from the other subtypes (83.8% accuracy with 86.0% positive predictive value and 81.4% negative predictive value, when the sensitivity and specificity are at their maximum values of the model). In the J-CASE data set, LV hypertrophy with a more extensive LV mass index but relatively modest interventricular septum thickening and enlargement of papillary muscle diameter significantly characterized ATTRwt-CA. These findings may lead to more accurate screening echocardiography for diagnosing ATTRwt-CA and motivate the subsequent comprehensive clinical diagnostic process, including multimodality imaging.

5 June 2020 in Heart and Vessels
Verified
Journal Article
Open access
PDF file
SKShuichi Kitada
Shuichi Kitada
YKYu Kawada
Yu Kawada
SOSatoshi Osaga
Satoshi Osaga
MKMarina Kato
Marina Kato
SKShohei Kikuchi
Shohei Kikuchi
NONobuyuki Ohte
Nobuyuki Ohte
Heart failure (HF) with mid-range left ventricular ejection fraction (LVEF) (HFmrEF) is considered a new category of HF and LVEF < 50%, which is the upper threshold of LVEF for HFmrEF, is thought to represent a mild decrease in LV contractile performance. We aimed to consider an LVEF threshold value to be taken as a surrogate for impairment of LV contractile performance, resulting in new-onset HF. We enrolled 398 patients with LVEF ≥ 40% that underwent cardiac catheterization. Using the LV pressure recording with a catheter-tipped micromanometer, we calculated the inertia force of late systolic aortic flow (IFLSAF), which was sensitive to the slight impairment in LV contractile performance. We evaluated the utility of the IFLSAF for predicting future cardiovascular death or hospitalization for HF. We performed a receiver operating characteristic (ROC) curve analysis to determine the best LVEF threshold value for distinguishing whether the LV maintained the IFLSAF. A multivariate Cox proportional-hazards model revealed that the loss of IFLSAF was significantly associated with the future adverse events (HR: 7.798, 95%CI 2.174–27.969,p = 0.002). According to the ROC curve analysis, an LVEF ≥ 58% indicated that the LV could maintain the IFLSAF. We concluded that the loss of IFLSAF, which could reflect even slight impairment in LV contractile performance, was a reliable indicator for new-onset HF in patients with LVEF ≥ 40%. LVEF ≥ 58% could be taken as a surrogate for the IFLSAF maintenance; this threshold could be useful for risk stratification of new-onset HF in patients with preserved LVEF.